JFJean-Baptiste Fassier

Jean-Baptiste Fassier

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Jean-Baptiste Fassier has a total of 312 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Promoting the Mental Health of Hospital Professionals Through a Workplace-Based Mindfulness Intervention: Protocol for a Randomized Controlled Pilot Trial With a Realist Evaluation (PROMIND)

    by Ludivine Nohales, Sandrine Touzet, Anne Termoz, Laurent Remontet, Lou-Anne Audouard, Marion Trousselard, Emmanuel Fort, Nathalie Streichenberger, Pascal Delamillieure, Antoine Lutz, et al.

    Background: Hospital professionals face mental health challenges caused by the high demands of their work. Mindfulness meditation (MM) is a nonpharmacological practice with promising effects in promoting mental health and well-being across various hospital professionals. However, the benefits obtained from its implementation in the context of real work in hospital departments are understudied. Objective: The aims of this pilot study are to implement and evaluate, at both the individual and collective levels, the exploratory outcomes of a workplace-based mindfulness intervention developed participatively for hospital teams in a French university hospital. The feasibility of the implementation of the intervention, the influence of the work environment, and the mechanisms through which it produces its effects will also be assessed. Methods: For this prospective interventional study, a preliminary co-construction with the stakeholders (a task force with professionals and management) made it possible to develop and adapt the intervention to the needs and capacities of the professionals, using the intervention mapping model for health program planning. Inclusion and an MM information meeting were proposed to 8 hospital departments, which were then randomized into 2 parallel cluster groups (intervention or control group). In the intervention group, an MM test session was proposed before committing to the MM program (10 one-hour sessions) for a maximum of 15 professionals per department. A convergent mixed methods design with concomitant quantitative and qualitative data collection was used, before integration of findings. Quantitative evaluation was based on a comparison of “before-after” measurements, with a comparison between intervention and control groups. The primary exploratory outcome was the evolution of psychological flourishing at work, which was measured using the adapted and validated French-language scale Psychological Flourishing at Work (EEPMT-8), to which the Professional Life Satisfaction Scale (ÉSVP-5) was added, to form a new 13-item Psychological Flourishing at Work Scale (EEPMT-13). Realist evaluation by qualitative methods explored the influence of contexts on the implementation (barrier and facilitators), and the links between context, mechanisms, and effects of MM. The study was approved by the Sud-Est VI ethics committee (Clermont Ferrand, France). Results: Funding was obtained in October 2021 and June 2024. This study was conducted from May 2024 to June 2025. As of May 2024, 108 participants were enrolled. Analyses are in progress. Results are expected to be published by the end of 2026. Conclusions: Participative approaches are essential for a challenged, tailored implementation of a workplace-based mindfulness intervention in hospital teams. The evaluation of the intervention with mixed methods and the characterization of both individual and organizational levels are aligned with the recommendations to evaluate a complex intervention in a workplace; challenges include the use of an innovative primary endpoint and methodological pluralism to plan for scalability at a subsequent stage.

  • Open Access

    REalist COllaborative eVAluation of a work disability prevention programme for breast cancer survivors: Protocol of the RECOVA-FASTRACS realist evaluation (Preprint)

    by Apolline Blazer, Sabrina Rouat, Laure Guittard, Pauline Drouin, Julien Péron, Béatrice Fervers, Julien Carretier, Guillaume Broc, Laurent Letrilliart, Jean-Baptiste Fassier, et al.

    Background: Women with breast cancer face many barriers to returning to work (RTW) after their treatment. The Facilitating and Sustaining the Return to Work After Breast Cancer (FASTRACS) intervention aims to facilitate and sustain functional RTW. Objective: The main objective of the RECOVA-FASTRACS (Realist Collaborative Evaluation of a Work Disability Prevention Program for Breast Cancer Survivors) study is to evaluate the processes using a realist approach that analyzes what works, how, for whom, and under what circumstances. Methods: The RECOVA-FASTRACS study uses a mixed methods design to assess the implementation, context, and impact mechanisms of the FASTRACS intervention. The qualitative analysis will include 2 main components: a trajectory analysis and a focus group assessment. The trajectory analysis will examine the experiences of women who participated in the intervention and key individuals involved in their RTW process. We will use semistructured interviews according to the multiple-case study method. Additionally, to explore organizational and professional practices, focus groups will be conducted with professionals who deliver the intervention. To analyze the trajectories, embedded and iterative integration will combine the qualitative findings with relevant quantitative data from the FASTRACS randomized controlled trial for 5 domains: personal situation, professional situation, RTW, care pathway, intervention tool use, and perceived usefulness. Results: The RECOVA-FASTRACS study received funding in 2022. Recruitment and qualitative data collection began in month 6. Final analyses are expected to be completed by the end of 2026, with dissemination of the main findings anticipated in late 2027. Conclusions: Our mixed methods realist evaluation will provide a detailed analysis of the intervention processes, helping to identify impact mechanisms within specific contexts. This approach is meant to ensure a more informed and realist deployment of the intervention by professionals following the study.

  • Open Access

    REalist COllaborative eVAluation of a work disability prevention programme for breast cancer survivors: Protocol of the RECOVA-FASTRACS realist evaluation (Preprint)

    by Apolline Blazer, Sabrina Rouat, Laure Guittard, Pauline Drouin, Julien Péron, Béatrice Fervers, Julien Carretier, Guillaume Broc, Laurent Letrilliart, Jean-Baptiste Fassier, et al.

    BACKGROUND Women with breast cancer face many barriers to return to work (RTW) after their treatment. The FAcilitating and SusTain the Return to work After breast Cancer (FASTRACS) intervention aims to facilitate and sustain functional RTW. OBJECTIVE The main objective of the RECOVA-FASTRACS study is to evaluate the processes of the using a realist approach that analyses what works, how, for whom and under what circumstances. METHODS The RECOVA-FASTRACS study uses a mixed-methods design to assess the implementation, context, and impact mechanisms of the FASTRACS intervention. The qualitative analysis will include two main components: a trajectory analysis and a focus group assessment. The trajectory analysis will examine the experience of women who participated in the intervention and key individuals involved in their RTW process. We will use semi-structured interviews according to the multiple-case study method. Additionally, to explore organisational and professional practices, focus groups will be conducted with professionals who deliver the intervention. RESULTS To analyse the trajectories, embedded and iterative integration will combine the qualitative findings, with relevant quantitative data from the FASTRACS randomised controlled trial for five domains (i.e. personal situation, professional situation, return to work, care pathway, intervention tool use and perceived usefulness). CONCLUSIONS Our mixed-methods realist evaluation will provide a detailed analysis of the intervention processes, helping to identify impact mechanisms within specific contexts. This approach is meant to ensure a more informed and realist deployment of the intervention by professionals following the study. CLINICALTRIAL

  • Open Access

    Using intervention mapping to facilitate and sustain return-to work after breast cancer: protocol for the FASTRACS multicentre randomized controlled trial

    by Jean-Baptiste Fassier, Laure Guittard, Béatrice Fervers, Sabrina Rouat, Philippe Sarnin, Julien Carretier, Guillaume Broc, Laurent Letrilliart, Julien Péron, Marion Lamort-Bouché

    Women with breast cancer face many barriers to return to work (RTW) after their cancer. The main objective of the FASTRACS-RCT is to evaluate the impact of the FASTRACS (Facilitate and Sustain Return to Work after Breast Cancer) intervention on the sustainable RTW of breast cancer patients, 12 months after the end of active treatment. FASTRACS-RCT is a prospective, national, multicentre, randomized, controlled and open-label study. A total of 420 patients with early breast cancer scheduled for surgery and (neo)adjuvant chemotherapy, will be randomly assigned (1:1 ratio) to: (i) the intervention arm comprising four steps over 6 months : Handing over the intervention tools; transitional medical consultation with the general practitioner (GP); pre-RTW visit with the company’s occupational physician (OP); catch-up visit with a hospital-based RTW expert (if sick leave > 10 months) (ii) the control arm to receive usual care. The design of the FASTRACS intervention was informed by intervention mapping for complex interventions in health promotion planning, and involved patients and representatives of relevant stakeholders. Specific tools were developed to bridge the gap between the hospital, the GP, the OP and the workplace: a toolkit for breast cancer patients comprising a theory-based guide; specific checklists for the GP and the OP, respectively; and a theory-based guide for workplace actors (employer, manager, colleagues). The primary endpoint will associate sustainable RTW (full-time or part-time work at 50% or more of working time, for at least 28 consecutive days) and days off work. It will be assessed at 4, 8 and 12 months after the end of active oncological treatment. Secondary endpoints will include quality of life, anxiety, depression, RTW self-efficacy, physical activity, social support, job accommodations, work productivity, job status, and the usefulness and acceptability of the intervention’s tools. FASTRACS-RCT will be supplemented by a realist evaluation approach aimed at understanding the influence of context in activating the intervention’s mechanisms and effects. If the expected impact of the intervention is confirmed, the intervention will be adapted and scaled-up for other cancers and chronic diseases to better integrate healthcare and work disability prevention. NCT04846972 ; April 15, 2021.


  • Open Access

    Combining SARS‐CoV‐2 interferon‐gamma release assay with humoral response assessment to define immune memory profiles

    by William Mouton, Guy Oriol, Christelle Compagnon, Carla Saade, Kahina Saker, Priscille Franc, Bouchra Mokdad, Aurore Fleurie, Xavier Lacoux, Soizic Daniel, et al.

    Objectives: In the post‐SARS‐CoV‐2 pandemic era, “breakthrough infections” are still documented, due to variants of concerns (VoCs) emergence and waning humoral immunity. Despite widespread utilization, the definition of the anti‐Spike (S) immunoglobulin‐G (IgG) threshold to define protection has unveiled several limitations. Here, we explore the advantages of incorporating T‐cell response assessment to enhance the definition of immune memory profile.Methods: SARS‐CoV‐2 interferon‐gamma release assay test (IGRA) was performed on samples collected longitudinally from immunocompetent healthcare workers throughout their immunization by infection and/or vaccination, anti‐receptor‐binding domain IgG levels were assessed in parallel. The risk of symptomatic infection according to cellular/humoral immune capacities during Omicron BA.1 wave was then estimated.Results: Close to 40% of our samples were exclusively IGRA‐positive, largely due to time elapsed since their last immunization. This suggests that individuals have sustained long‐lasting cellular immunity, while they would have been classified as lacking protective immunity based solely on IgG threshold. Moreover, the Cox regression model highlighted that Omicron BA.1 circulation raises the risk of symptomatic infection while increased anti‐receptor‐binding domain IgG and IGRA levels tended to reduce it.Conclusion: The discrepancy between humoral and cellular responses highlights the significance of assessing the overall adaptive immune response. This integrated approach allows the identification of vulnerable subjects and can be of interest to guide antiviral prophylaxis at an individual level.


  • Open Access

    Planning Individual and Population-Based Interventions in Global Health: Applying the DEA-A Framework to Promote Behavioral, Emotional, and/or Cognitive Change among Stakeholders

    by Guillaume Broc, Jean Baptiste Fassier, Stéphane Raffard, Olivier Lareyre

    Addressing health challenges that impact human well-being requires a comprehensive, interdisciplinary approach that would be at the crossroad of population-based prevention and individual-level clinical care, which is in line with a Global Health perspective. In the absence of a unifying theoretical framework to guide such interventions, a Dynamic Ecosystem Adaptation through the Allostasis (DEA-A) framework has been proposed, emphasizing the functional adaptation of individuals and organizations in symbiosis with their living ecosystem. While a conceptual model has been presented, this methodological contribution aims at illustrating the practical application of the DEA-A framework for planning Global Health interventions. The methodology combines Intervention Mapping and Cognitive and Behavioral Theory, extended to the ecosystem. Practical guidelines and supporting tools are provided to help public health providers and clinicians in establishing a functional ecosystem diagnosis of the issue; defining not only behavioral, but also emotional and cognitive change objectives (allostasis targets) expected for each stakeholder; and designing intervention plans targeting determinants of these allostasis. The discussion addresses implementation and evaluation perspectives of interventions based on the DEA-A framework, emphasizing the importance of considering change in its processual and ecosystem complexity. Lastly, encouragements for a deeper understanding of individual and ecosystem homeostasis/allostasis processes are made in order to promote more functional interventions.


  • Open Access

    Glove-related contact dermatitis: diagnostic value of a repeated application test

    by Céline Lamouroux, Léa Bertolotti, Clio Coste, Pauline Pralong, Marine-Alexia Lefevre, Justine Pasteur, Aude Clément, Marie-Christine Ferrier Le Bouëdec, Barbara Charbotel, Jean-Baptiste Fassier, et al.

    Background: Gloves are frequently the cause of occupational hand dermatitis and are responsible for irritant (ICD) and allergic contact dermatitis (ACD). The diagnosis of ACD is based on patch tests to gloves (PTg), semi-open tests to gloves (SOg), and patch tests to glove allergens (PTal). Objective: The aim was to define the contribution of a glove repeated application test (GRAT) in the diagnosis strategy of glove-related contact dermatitis. Methods: This retrospective study included patients with hand eczema who wore gloves and who completed a GRAT in the context of allergological explorations. It consisted of applying a piece of the glove maintained by a non-adhesive strip during 10 consecutive nights on the same area of the anterior face of the forearm. Results: Ten patients were diagnosed with ACD to gloves. This diagnosis was made on positive SOg, PTg, GRAT and PTal for 2 patients, positive PTal and GRAT for 3 patients, positive SOg and GRAT for 2 patients, positive GRAT alone for 2 patients, positive PTal alone for 1 patient. The GRAT had better sensitivity than the other tests. Conclusion: GRAT seems useful in the diagnostic strategy of glove contact dermatitis and could be proposed when the diagnosis of glove-related contact dermatitis is suspected.


  • Prior SARS-CoV-2 infection enhances and reshapes spike protein–specific memory induced by vaccination

    by Véronique Barateau, Loïc Peyrot, Carla Saade, Bruno Pozzetto, Karen Brengel-Pesce, Mad-Hélénie Elsensohn, Omran Allatif, Nicolas Guibert, Christelle Compagnon, Natacha Mariano, et al.

    The diversity of vaccination modalities and infection history are both variables that have an impact on the immune memory of individuals vaccinated against SARS-CoV-2. To gain more accurate knowledge of how these parameters imprint on immune memory, we conducted a long-term follow-up of SARS-CoV-2 spike protein–specific immune memory in unvaccinated and vaccinated COVID-19 convalescent individuals as well as in infection-naïve vaccinated individuals. Here, we report that individuals from the convalescent vaccinated (hybrid immunity) group have the highest concentrations of spike protein–specific antibodies at 6 months after vaccination. As compared with infection-naïve vaccinated individuals, they also display increased frequencies of an atypical mucosa-targeted memory B cell subset. These individuals also exhibited enhanced T H 1 polarization of their SARS-CoV-2 spike protein–specific follicular T helper cell pool. Together, our data suggest that prior SARS-CoV-2 infection increases the titers of SARS-CoV-2 spike protein–specific antibody responses elicited by subsequent vaccination and induces modifications in the composition of the spike protein–specific memory B cell pool that are compatible with enhanced functional protection at mucosal sites.


  • Open Access

    A third vaccine dose equalizes the levels of effectiveness and immunogenicity of heterologous or homologous COVID-19 vaccine regimens

    by Nicolas Guibert, Kylian Trepat, Bruno Pozzetto, Laurence Josset, Jean-Baptiste Fassier, Omran Allatif, Kahina Saker, Karen Brengel-Pesce, Thierry Walzer, Philippe Vanhems, et al.

    Backgroung To cope with the persistence of the Covid-19 epidemic and the decrease in antibody levels following vaccination, a third dose of vaccine has been recommended in the general population. However, several vaccine regimens had been used initially, and the heterologous ChadOx1-S/BNT162b2 regimen had shown better efficacy and immunogenicity than the homologous BNT162b2/BNT162b2 regimen. Aim We wanted to determine if this benefit was retained after the third dose. Methods We combined an observational study of SARS-COV-2 infections among vaccinated healthcare workers at the University-Hospital of Lyon, France, with an analysis of immunological parameters before and after the third mRNA vaccine dose. Results Following the second vaccine dose, heterologous vaccination regimens were more protective against infection than homologous regimens, but this was no longer the case after the third dose. RBD-specific IgG levels and serum neutralization capacity against different SARS-CoV-2 variants were higher after the third dose than after the second dose in the homologous regimen group, but not in the heterologous group. Conclusion The advantage conferred by heterologous vaccination is lost after the third dose both in terms of protection and immunogenicity. Immunological measurements suggest that heterologous vaccination induces maximal immunity after the second dose, whereas the third dose is required to reach the same level in individuals with a homologous regimen.